Efficacy and Safety of 8-Weeks of Glecaprevir/Pibrentasvir in Treatment-Naive Adults with HCV Genotype 1-6 and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤1

被引：0

作者：

Fontana, Robert J. ^{[1
]}

Lens, Sabela ^{[2
,3
]}

McPherson, Stuart ^{[4
,5
]}

Elkhashab, Magdy ^{[6
]}

Katzarov, Krum ^{[7
]}

Pires, Ana Gabriela ^{[8
]}

Xue, Zhenyi ^{[8
]}

Trinh, Roger ^{[8
]}

Rodrigues, Lino, Jr. ^{[8
]}

Porcalla, Ariel ^{[8
]}

Zeuzem, Stefan ^{[9
]}

机构：

[1] Univ Michigan, Div Gastroenterol & Hepatol, Ann Arbor, MI 48109 USA

[2] Idibaps, Hosp Clin, Liver Unit, Barcelona, Spain

[3] Ciberehd, Madrid, Spain

[4] Newcastle Upon Tyne Hosp NHS Fdn & Trust, Liver Unit, Newcastle Upon Tyne, Tyne & Wear, England

[5] Newcastle Univ, Newcastle Upon Tyne, Tyne & Wear, England

[6] Toronto Liver Ctr, Toronto, ON, Canada

[7] Mil Med Acad, Dept Gastroenterol Hepatopancreatobiliary HPB Sur, Belgrade, Serbia

[8] Abbvie Inc, N Chicago, IL USA

[9] Goethe Univ Frankfurt, Frankfurt, Germany

来源：

HEPATOLOGY | 2018年 / 68卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

653

引用

页码：388A / 389A

页数：2

共 50 条

[41] SAFETY AND EFFICACY OF TREATMENT WITH THE INTERFERON-FREE, RIBAVIRIN-FREE COMBINATION OF SOFOSBUVIR + GS-5816 FOR 12 WEEKS IN TREATMENT NAIVE PATIENTS WITH GENOTYPE 1-6 HCV INFECTION
Everson, G. T.
Tran, T. T.
Towner, W. J.
Davis, M. N.
Wyles, D.
Nahass, R.
McNally, J.
Brainard, D. M.
Han, L.
Doehle, B.
Mogalian, E.
Symonds, W. T.
McHutchison, J. G.
Morgan, T.
Chung, R. T.
JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S46 - S46
[42] High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1-6 patients without cirrhosis
Puoti, Massimo
Foster, Graham R.
Wang, Stanley
Mutimer, David
Gane, Edward
Moreno, Christophe
Chang, Ting Tsung
Lee, Samuel S.
Marinho, Rui
Dufour, Jean-Francois
Pol, Stanislas
Hezode, Christophe
Gordon, Stuart C.
Strasser, Simone I.
Thuluvath, Paul J.
Zhang, Zhenzhen
Lovell, Sandra
Pilot-Matias, Tami
Mensa, Federico J.
JOURNAL OF HEPATOLOGY, 2018, 69 (02) : 293 - 300
[43] Efficacy and safety of glecaprevir/pibrentasvir treatment for 8 weeks in treatment-naive patients with chronic hepatitis C virus infection without cirrhosis or with compensated cirrhosis: Analysis of data pooled from phase 2 and 3 studies
Zuckerman, Eli
Gutierrez, Julio
Ustianowski, Andrew
Naggie, Susanna
Caruntu, Florin Alexandru
Ravendhran, Natarajan
Sigal, Samuel
Barrett, Lisa
Cohen, Stanley
Crown, Eric
Dylla, Doug
Fredrick, Linda
Wang, Stanley
Porcalla, Ariel
Mensa, Federico
Bruno, Savino
JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E251 - E251
[44] Safety and Efficacy of Velpatasvir and Sofosbuvir-based Regimens for the Treatment of HCV Genotype 1-6: Results of the HCV-TARGET Study
Landis, Charles S.
Sulkowski, Mark S.
Reau, Nancy
Lutchman, Glen A.
Vainorius, Monika
Welzel, Tania M.
Zeuzem, Stefan
Khalili, Mandana
Nelson, David R.
Lok, Anna S.
Fried, Michael W.
Terrault, Norah
HEPATOLOGY, 2017, 66 : 587A - 587A
[45] Efficacy and safety of grazoprevir plus ribavirin for 12 or 24 weeks in treatment-naive patients with hepatitis C virus genotype 1 infection
Gane, E.
Ben Ari, Z.
Mollison, L.
Zuckerman, E.
Bruck, R.
Baruch, Y.
Howe, A. Y. M.
Wahl, J.
Bhanja, S.
Hwang, P.
Zhao, Y.
Robertson, M. N.
JOURNAL OF VIRAL HEPATITIS, 2016, 23 (10) : 789 - 797
[46] EFFICACY AND SAFETY OF GLECAPREVIR/PIBRENTASVIR TREATMENT FOR 8 WEEKS IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS: ANALYSIS OF DATA POOLED FROM PHASE 2 AND 3 STUDIES
Gutierrez, Julio
Zuckerman, Eli
Ustianowski, Andrew
Naggie, Susanna
Caruntu, Florin
Ravendhran, Natarajan
Sigal, Samuel
Barrett, Lisa
Cohen, Stanley M.
Crown, Eric
Dylla, Doug
Fredrick, Linda
Wang, Stanley
Porcalla, Ariel R.
Mensa, Federico
Bruno, Savino
GASTROENTEROLOGY, 2019, 156 (06) : S1218 - S1218
[47] SHORT DURATION TREATMENT WITH SOFOSBUVIR/VELPATASVIR PLUS GS-9857 IN TREATMENT-NAIVE GENOTYPE 1-6 HCV-INFECTED PATIENTS WITH OR WITHOUT CIRRHOSIS
Gane, E. J.
Nguyen, M.
Kwo, P.
Kowdley, K.
Reau, N.
Jacobson, I.
Curry, M.
Pearlman, B.
Khalid, O.
Everson, G.
Gordon, S.
Poulos, J.
Sheikh, A.
Bernstein, D.
Yang, J. C.
Stamm, L. M.
An, D.
Dvory-Sobol, H.
Brainard, D. M.
McHutchison, J. G.
Tong, M.
Tsai, N.
Beavers, K. L.
Rabinovitz, M.
Shiffman, M.
Stedman, C.
Lawitz, E.
JOURNAL OF HEPATOLOGY, 2016, 64 : S758 - S759
[48] EXPEDITION-I: efficacy and safety of glecaprevir/pibrentasvir in adults with chronic hepatitis C virus genotype 1, 2, 4, 5 or 6 infection and compensated cirrhosis
Forns, X.
Lee, S.
Valdes, J.
Lens, S.
Ghalib, R.
Aguilar, H.
Felizarta, F.
Hassanein, T.
Hinrichsen, H.
Rincon, D.
Morillas, R.
Zeuzem, S.
Horsmans, Y.
Nelson, D.
Yu, Y.
Pilot-Matias, T.
Lin, C. -W.
Mensa, F.
JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S3 - S4
[49] EXPEDITION-I: EFFICACY AND SAFETY OF GLECAPREVIR/PIBRENTASVIR IN ADULTS WITH CHRONIC HEPATITIS C VIRUS GENOTYPE 1, 2, 4, 5 OR 6 INFECTION AND COMPENSATED CIRRHOSIS
Forns, Xavier
Lee, Sam
Valdes, Joaquin M.
Lens, Sabela
Ghalib, Reem
Aguilar, Humberto
Felizarta, Franco
Hassanein, Tarek I.
Hinrichsen, Holger
Rincon, Diego
Morillas, Rosa M.
Zeuzem, Stefan
Horsmans, Yves
Nelson, David R.
Yu, Yao
Pilot-Matias, Tami
Lin, Chih-Wei
Mensa, Federico
GASTROENTEROLOGY, 2017, 152 (05) : S1061 - S1061
[50] SAFETY AND EFFICACY OF SOFOSBUVIR/VELPATASVIR/VOXILAPREVIR-BASED REGIMENS FOR THE TREATMENT OF HCV GENOTYPE 1-6: RESULTS OF THE HCV-TARGET COHORT
Zeuzem, Stefan
Sulkowski, Mark S.
Lim, Joseph K.
Morelli, Giuseppi
Khalili, Mandana
Brown, Robert S., Jr.
Ben-Ari, Ziv
Park, James S.
Reddy, K. Rajender
Shiffman, Mitchell L.
Dong, Meichen
Vainorius, Monika
Fried, Michael W.
Nelson, David R.
Terrault, Norah
HEPATOLOGY, 2019, 70 : 939A - 940A

← 1 2 3 4 5 →